FDA Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites: Testing Presence, Prominence,...

Area of Science:

• Pharmaceutical regulatory affairs
• Health communication
• Patient advocacy

Background:

• The US Food and Drug Administration (FDA) uses accelerated approval for drugs treating serious illnesses like cancer.
• Direct-to-consumer websites for these drugs often include disclosures about accelerated approval.
• Understanding these disclosures is crucial for informed patient decision-making.

Purpose of the Study:

• To evaluate the impact of accelerated approval disclosure wording and prominence on consumer comprehension.
• To compare consumer-friendly disclosures with physician-labeling disclosures and a control condition.
• To assess how different disclosure formats affect understanding of key accelerated approval concepts.

Main Methods:

• Two studies were conducted with US adults (N=822 general population, N=615 cancer patients/caregivers).
• Participants viewed websites for a fictitious leukemia drug with varied disclosure conditions (control, physician-labeling, consumer-friendly; low/high prominence).
• Comprehension of accelerated approval concepts was measured across conditions.

Main Results:

• Consumer-friendly disclosures significantly improved understanding of accelerated approval concepts compared to physician-labeling disclosures.
• While both disclosure types increased awareness, only consumer-friendly wording enhanced comprehension.
• Increasing disclosure prominence had minimal impact on participant understanding.

Conclusions:

• Implementing consumer-friendly disclosures on prescription drug websites can enhance patient and caregiver understanding of accelerated approval.
• Clearer communication is vital for informed decision-making regarding cancer treatments.
• Future research should explore optimal methods for conveying complex regulatory information to the public.